These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 26660428)

  • 1. Emerging therapeutic drugs for AML.
    Stein EM; Tallman MS
    Blood; 2016 Jan; 127(1):71-8. PubMed ID: 26660428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.
    Kung Sutherland MS; Walter RB; Jeffrey SC; Burke PJ; Yu C; Kostner H; Stone I; Ryan MC; Sussman D; Lyon RP; Zeng W; Harrington KH; Klussman K; Westendorf L; Meyer D; Bernstein ID; Senter PD; Benjamin DR; Drachman JG; McEarchern JA
    Blood; 2013 Aug; 122(8):1455-63. PubMed ID: 23770776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational CD33-targeted therapeutics for acute myeloid leukemia.
    Walter RB
    Expert Opin Investig Drugs; 2018 Apr; 27(4):339-348. PubMed ID: 29534618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia.
    Flach J; Shumilov E; Wiedemann G; Porret N; Shakhanova I; Bürki S; Legros M; Joncourt R; Pabst T; Bacher U
    Hematol Oncol; 2020 Oct; 38(4):425-431. PubMed ID: 32306411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How I treat acute myeloid leukemia in the era of new drugs.
    DiNardo CD; Wei AH
    Blood; 2020 Jan; 135(2):85-96. PubMed ID: 31765470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01.
    Miyamoto K; Minami Y
    Int J Clin Oncol; 2019 Aug; 24(8):893-898. PubMed ID: 31111287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updates on DNA methylation modifiers in acute myeloid leukemia.
    Contieri B; Duarte BKL; Lazarini M
    Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Treatment Paradigms in Acute Myeloid Leukemia.
    Khanal N; Upadhyay Banskota S; Bhatt VR
    Clin Pharmacol Ther; 2020 Sep; 108(3):506-514. PubMed ID: 32572947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drug approvals in acute myeloid leukemia: an unprecedented paradigm shift.
    Kopmar NE; Estey EH
    Clin Adv Hematol Oncol; 2019 Oct; 17(10):569-575. PubMed ID: 31730583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [What is recommended in the treatment of acute myeloid leukemia?].
    Thol F
    Internist (Berl); 2019 Dec; 60(12):1240-1250. PubMed ID: 31690995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.
    DiNardo CD; Stein EM
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):769-772. PubMed ID: 30416011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What are the most promising new agents in acute myeloid leukemia?
    Sallman DA; Lancet JE
    Curr Opin Hematol; 2017 Mar; 24(2):99-107. PubMed ID: 28030373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine.
    Lam SS; He AB; Leung AY
    Blood Rev; 2017 Nov; 31(6):418-425. PubMed ID: 28797519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
    Bewersdorf JP; Stahl M; Zeidan AM
    Leuk Lymphoma; 2019 Jun; 60(6):1354-1369. PubMed ID: 30652518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.
    Long L; Assaraf YG; Lei ZN; Peng H; Yang L; Chen ZS; Ren S
    Drug Resist Updat; 2020 Sep; 52():100703. PubMed ID: 32599434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AML treatment: conventional chemotherapy and emerging novel agents.
    Forsberg M; Konopleva M
    Trends Pharmacol Sci; 2024 May; 45(5):430-448. PubMed ID: 38643058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
    Richardson DR; Green SD; Foster MC; Zeidner JF
    Curr Hematol Malig Rep; 2021 Feb; 16(1):97-111. PubMed ID: 33609248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance.
    Grimwade D; Ivey A; Huntly BJ
    Blood; 2016 Jan; 127(1):29-41. PubMed ID: 26660431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.
    Short NJ; Konopleva M; Kadia TM; Borthakur G; Ravandi F; DiNardo CD; Daver N
    Cancer Discov; 2020 Apr; 10(4):506-525. PubMed ID: 32014868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.